文献速递其他结缔组织病

系统性硬化症相关间质性肺病进展:KL-6与CCL18肺蛋白标志物的重要性

Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
PubMed 文献 · Arthritis Rheumatol · 2019-11-01

本研究基于硬皮病肺研究II(SLS II)队列,分析基线及12个月血浆KL-6和CCL18水平与系统性硬化症相关间质性肺病(SSc-ILD)严重程度及进展的关系。结果显示基线KL-6和CCL18均与影像学纤维化范围相关,且两者水平在1年时显著下降;在CYC和MMF两个治疗臂中,较高的基线KL-6和CCL18水平均预测FVC和DLco的下降轨迹及疾病进展,CCL18还预测CYC臂死亡率。

要点

  • 基线KL-6和CCL18水平与SSc-ILD影像学纤维化范围相关。
  • 两标志物在免疫抑制治疗1年后均显著下降。
  • 较高基线KL-6和CCL18预测FVC及DLco的进展,CCL18还预测CYC臂死亡率。

核心结论

  • 在严格实施的SSc-ILD临床试验中,KL-6和CCL18水平与ILD严重程度相关,并随免疫抑制治疗而下降。
  • 基线KL-6和CCL18较高的患者尽管接受治疗仍更可能发生疾病进展。
  • KL-6和CCL18可用于识别具有进展性ILD表型、可能受益于更积极初始治疗的患者。

研究设计与样本

  • 纳入硬皮病肺研究II(SLS II)中接受环磷酰胺(CYC)或霉酚酸酯(MMF)治疗的患者。
  • 采用酶联免疫吸附试验分析基线和12个月血浆KL-6与CCL18水平。
  • 每3个月测量用力肺活量(FVC)和一氧化碳弥散量(DLco)。
  • 建立联合模型分析基线KL-6和CCL18水平与1年内FVC和DLco变化轨迹的关系,并按治疗臂分层。

主要发现

  • 基线KL-6和CCL18水平均与影像学纤维化范围相关。
  • CCL18和KL-6水平在1年时均显著下降。
  • 在CYC臂(n=71)和MMF臂(n=62)中,较高基线KL-6水平预测1年内FVC进展(CYC P=0.024;MMF P=0.005)和DLco进展(CYC P<0.001;MMF P=0.004)。
  • 较高基线CCL18水平预测1年内FVC进展(CYC P<0.001;MMF P=0.007)和DLco进展(CYC P=0.001;MMF P<0.001),并预测死亡率(仅CYC臂 P=0.0008)。

关键数值与推荐

  • 基线KL-6预测FVC进展:CYC臂P=0.024,MMF臂P=0.005。
  • 基线KL-6预测DLco进展:CYC臂P<0.001,MMF臂P=0.004。
  • 基线CCL18预测FVC进展:CYC臂P<0.001,MMF臂P=0.007。
  • 基线CCL18预测DLco进展:CYC臂P=0.001,MMF臂P<0.001。
  • 基线CCL18预测死亡率:仅CYC臂P=0.0008。

临床怎么用

  • KL-6和CCL18可作为评估SSc-ILD严重程度和进展风险的血清标志物。
  • 基线KL-6或CCL18较高的SSc-ILD患者可考虑更积极的初始免疫抑制治疗。
  • 动态监测KL-6和CCL18水平可能有助于评估免疫抑制治疗反应。

局限性

  • 研究基于SLS II临床试验队列,样本限于接受CYC或MMF治疗的SSc-ILD患者。
  • 随访时间为1年,长期预后价值未明确。
  • 联合模型分析中死亡率预测仅在CYC臂显著,MMF臂未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the relationship between Krebs von den Lungen 6 (KL-6) and CCL18 levels and the severity and progression of systemic sclerosis (SSc)-related interstitial lung disease (ILD). METHODS: Patients enrolled in the Scleroderma Lung Study II (cyclophosphamide [CYC] versus mycophenolate mofetil [MMF]) were included. Baseline and 12-month plasma samples were analyzed by enzyme-linked immunosorbent assay to assess CCL18 and KL-6 levels. The forced vital capacity (FVC) and the diffusing capacity for carbon monoxide (DLco) were measured every 3 months. Joint models were created to investigate the relationship between baseline CCL18 and KL-6 levels and the course of the FVC and DLco over 1 year according to treatment arm. RESULTS: Baseline KL-6 and CCL18 levels each correlated with the extent of radiographic fibrosis. Levels of both CCL18 and KL-6 declined significantly at 1 year. In both treatment arms (n = 71 for CYC, n = 62 for MMF), a higher baseline KL-6 level predicted progression of ILD based on the course of FVC (P = 0.024 for CYC; P = 0.005 for MMF) and DLco (P < 0.001 for CYC; P = 0.004 for MMF) over 1 year. A higher baseline CCL18 level predicted progression of ILD based on the course of the FVC (P < 0.001 for CYC; P = 0.007 for MMF) and DLco (P = 0.001 for CYC; P < 0.001 for MMF) over 1 year, as well as mortality (P = 0.0008 for CYC arm only). CONCLUSION: In a rigorously conducted clinical trial for SSc-related ILD, KL-6 and CCL18 levels correlated with ILD severity and declined with immunosuppression. Patients with higher baseline KL-6 and CCL18 levels were more likely to experience disease progression despite treatment. KL-6 and CCL18 levels could be used to identify patients with a progressive ILD phenotype who may benefit from a more aggressive initial treatment approach.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Volkmann ER, Tashkin DP, Kuwana M, et al. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis Rheumatol. 2019. PMID: 31233287. doi:10.1002/art.41020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。